153 related articles for article (PubMed ID: 29138278)
1. A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.
Wang L; Collings CK; Zhao Z; Cozzolino KA; Ma Q; Liang K; Marshall SA; Sze CC; Hashizume R; Savas JN; Shilatifard A
Genes Dev; 2017 Oct; 31(20):2056-2066. PubMed ID: 29138278
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex.
Lee JH; Tate CM; You JS; Skalnik DG
J Biol Chem; 2007 May; 282(18):13419-28. PubMed ID: 17355966
[TBL] [Abstract][Full Text] [Related]
3. Histone H3K4 methylation-dependent and -independent functions of Set1A/COMPASS in embryonic stem cell self-renewal and differentiation.
Sze CC; Cao K; Collings CK; Marshall SA; Rendleman EJ; Ozark PA; Chen FX; Morgan MA; Wang L; Shilatifard A
Genes Dev; 2017 Sep; 31(17):1732-1737. PubMed ID: 28939616
[TBL] [Abstract][Full Text] [Related]
4. Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS.
Wu M; Wang PF; Lee JS; Martin-Brown S; Florens L; Washburn M; Shilatifard A
Mol Cell Biol; 2008 Dec; 28(24):7337-44. PubMed ID: 18838538
[TBL] [Abstract][Full Text] [Related]
5. Molecular regulation of histone H3 trimethylation by COMPASS and the regulation of gene expression.
Schneider J; Wood A; Lee JS; Schuster R; Dueker J; Maguire C; Swanson SK; Florens L; Washburn MP; Shilatifard A
Mol Cell; 2005 Sep; 19(6):849-56. PubMed ID: 16168379
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a synthetic lethality interaction between SETDB1 histone methyltransferase and CHD4 chromatin remodeling protein in a triple negative breast cancer cell line.
Moraes-Almeida MS; Sogayar MC; Demasi MAA
Braz J Med Biol Res; 2023; 56():e12854. PubMed ID: 37970920
[TBL] [Abstract][Full Text] [Related]
8. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
9. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
[TBL] [Abstract][Full Text] [Related]
10. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
12. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
13. Heterochromatin assembly and transcriptome repression by Set1 in coordination with a class II histone deacetylase.
Lorenz DR; Meyer LF; Grady PJ; Meyer MM; Cam HP
Elife; 2014 Dec; 3():e04506. PubMed ID: 25497836
[TBL] [Abstract][Full Text] [Related]
14. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
[TBL] [Abstract][Full Text] [Related]
15. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Kumar A; Kumari N; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2018 Oct; 674():31-36. PubMed ID: 29944950
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitylation of the COMPASS component Swd2 links H2B ubiquitylation to H3K4 trimethylation.
Vitaliano-Prunier A; Menant A; Hobeika M; Géli V; Gwizdek C; Dargemont C
Nat Cell Biol; 2008 Nov; 10(11):1365-71. PubMed ID: 18849979
[TBL] [Abstract][Full Text] [Related]
18. Conditioned medium from stimulated macrophages inhibits growth but induces an inflammatory phenotype in breast cancer cells.
Song W; Thakor P; Vesey DA; Gobe GC; Morais C
Biomed Pharmacother; 2018 Oct; 106():247-254. PubMed ID: 29966967
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
